Phosphoproteomics reveals ALK promote cell progress via RAS/JNK pathway in neuroblastoma
Kai Chen(XinHua Hospital), Zhixiang Wu(XinHua Hospital)
Cited by 16
Related Papers
XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor
|Journal of Experimental & Clinical Cancer Research|2021|29
P300 Interacted With N-Myc and Regulated Its Protein Stability via Altering Its Post-Translational Modifications in Neuroblastoma
|Molecular & Cellular Proteomics|2023|15